Cardiac Autonomic Neuropathy in Patients With Metabolic Syndrome (CAN)

Inclusion Criteria:

1. Subjects must have IGT or IFG and two other criteria of metabolic syndrome as defined by ATP III (IFG=fasting glucose ≥ 100 mg/dl (5.5 mmol/l))
2. Definition of IGT/IFG: IGT/IFG will be defined based on the ADA diagnostic guidelines following an oral glucose tolerance test (OGTT) [2].

3. Other Required Criteria (2 of the following):

   • Waist circumference ≥ 102 cm (40 inches) in men and ≥ 88 cm (35 inches) in women, {for Asian-Americans: men ≥ 88 cm (35 inches), women ≥ 78 cm (31 inches)}
   • Triglycerides ≥ 150 mg/dl (1.7 mmol/l) - patients on drug treatment with fibrates or nicotinic acid will be presumed to have triglycerides ≥ 150mg/dl and low HDL
   • HDL cholesterol < 40 mg/dl (1.0 mmol/l) in men and < 50 mg/dl (1.3 mmol/l) in women,
   • Blood pressure ≥ 130/≥ 85 mmHg
4. Age 18-65
5. Women of childbearing potential must be using contraception to prevent pregnancy

Exclusion Criteria:

1. Patients either pregnant or planning to become pregnant will be excluded

   • Women of childbearing potential will have a urine pregnancy test as part of the screening visit
   • Subjects who become pregnant during the study will undergo an exit visit and management of their IGT and Metabolic Syndrome will be returned to their primary care provider

2. Subjects with pre-existing cardiovascular disease including:

   • myocardial infarction
   • congestive heart failure
   • known arrhythmias
   • ventricular structural abnormalities and valvular disease
   • peripheral vascular disease
3. Subjects with hypoxemic lung or heart disease
4. Subjects with established diabetes
5. Laboratory evidence for a disease known to cause neuropathy within 3 months of screening will be an exclusion (those without known abnormality or those with a remote abnormality (> 3 months) will undergo the serologic screening)
6. Significant neurological disease (e.g., Parkinson's disease, epilepsy, recent stroke)
7. Subjects taking drugs which interfere with the uptake or metabolism of catecholamines
8. Subjects with known history of chronic kidney disease or who have significant hepatic disease (AST, ALT > 3 times upper limit for normal) or a history of previous kidney, pancreas or cardiac transplantation.
9. Subjects having taken systemic investigational drugs within the last 6 months
10. Inability or unwillingness of subject or legal guardian/representative to give written informed consent